ImmuPharma CEO confident on P140 partnership as strong pharma interest extends timeline into 2026

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy talked with Proactive's Stephen Gunnion about the company's ongoing discussions to secure a partnership for its lead asset, P140. McCarthy addressed investor concerns following a recent update that indicated the timing of a potential deal may now move into 2026. He explained that while the company had initially targeted the end of 2025 for deal completion, the timeline adjustment reflects strong ongoing engagement with multiple pharmaceutical companies—some of which include top ten global players. “We were all very pleasantly surprised [by] the amount of interest and positive interest from the pharma companies,” McCarthy stated. The discussions follow the September filing of a new patent for P140, which was based on a “groundbreaking discovery” made by the company’s scientific team. McCarthy emphasised that the scientific and commercial value of P140 remains unchanged, and that the company is focused on finding the right partner and structure for shareholders. He also provided reassurance regarding ImmuPharma’s financial position. Recent R&D tax credits, exercised warrants, and completion of a Lanstead share agreement have extended the company’s cash runway well into Q4 2026. McCarthy confirmed there is “no intention at all” to raise new funds via the market. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmuPharma #P140 #BiotechNews #PharmaDeals #DrugDevelopment #TimMcCarthy #BiotechInvesting #LupusTreatment #Pharmaceuticals #ClinicalResearch #StockMarketNews #InvestorUpdates